Biotech Values

[dewophile]

HCV

I would note that the title of #3 can be decieving. the "telaprevir alone" arm is followed by a course of peg/riba, so it is not really testing the efficacy of a non-SOC containing regimen

PS: interim data from BMY's combination study in nulls will be out at AASLD. however, i don't expect any SVR data - which is really going to be the ultimate test for non-SOC containing regimens since relapse without an immunomodulator is the biggest question mark surrounding any regimen without peg and/or riba